This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Pharmathene, Inc.. Active years: 2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2017
Title: David Woodhouse: Innovator in Anthrax Vaccine Formulation
Introduction
David Woodhouse is a notable inventor based in Yarm, Great Britain. With a focus on innovative solutions in pharmaceuticals, he has made significant contributions to the field of vaccine development, particularly in the fight against anthrax.
Latest Patents
Woodhouse holds a patent for an anthrax vaccine formulation and its uses. The invention details a vaccine that incorporates alhydrogel as an adjuvant. The composition is achieved by mixing recombinant protective antigen (rPA) with colloidal alhydrogel (alum) adjuvant. This innovative formulation consists of 200 µg/ml rPA, bound to 0.26% alhydrogel in phosphate buffered saline (PBS), ensuring an optimal concentration of phosphate. The patent also outlines methods for utilizing this vaccine to effectively treat or prevent infections caused by anthrax.
Career Highlights
David Woodhouse's work is closely associated with Pharmathene, Inc., a company that specializes in the development of biological and pharmaceutical products. His patent represents a significant advancement in medical science, enhancing the capabilities of vaccines to combat dangerous infections.
Collaborations
Throughout his career, Woodhouse has collaborated with talented professionals such as Allan Watkinson and Robert Wilson. These partnerships have contributed to the successful development of his patented vaccine formulation and further advancements in the field.
Conclusion
David Woodhouse is a dedicated inventor whose work in anthrax vaccine formulation showcases his commitment to innovative healthcare solutions. His patent not only highlights his expertise but also sets the stage for further research and development in vaccine technology. With continued efforts, he and his collaborators hold the potential to impact public health significantly.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile